| 2026-06-17 | 8-K | 10.1 | Second Amendment to the Insight Molecular Diagnostics Inc. Amended and Restated 2018 Equity Incentive Plan |
|---|
| 2026-02-12 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated as of February 10, 2026, by and between the Company and the purchasers thereto.* |
|---|
| 2025-10-02 | 8-K | 10.1 | Amendment to Employment Agreement, effective September 29, 2025, by and between Insight Molecular Diagnostics Inc. and Ekkehard Schütz. |
|---|
| 2025-02-10 | 8-K | 10.3 | Securities Purchase Agreement, dated February 7, 2025, by and among the Company and the investors signatory thereto. |
|---|
| 2025-02-10 | 8-K | 10.2 | Registration Rights Agreement, dated February 7, 2025, by and among the Company and the investors signatory thereto. |
|---|
| 2025-02-10 | 8-K | 10.1 | Securities Purchase Agreement, dated February 7, 2025, by and among the Company and the investors signatory thereto. |
|---|
| 2025-01-08 | 8-K | 10.1 | Amendment to and Waiver of Right to Extend Original Lease, dated as of December 26, 2024, effective as of January 2, 2025, by and among Oncocyte Corporation, Induce Biologics USA, Inc. and Cushing Ventures, LLC. |
|---|
| 2024-11-12 | 10-Q | 10.6 | Memorandum of Understanding, dated November 8, 2024, between the Company and Bio-Rad Laboratories, Inc. |
|---|
| 2024-10-15 | 8-K | 10.1 | Amended and Restated 2018 Equity Incentive Plan |
|---|
| 2024-10-03 | 8-K | 10.2 | Registration Rights Agreement, dated October 2, 2024, by and among the Company and the investors signatory thereto. |
|---|
| 2024-10-03 | 8-K | 10.1 | Securities Purchase Agreement, dated October 2, 2024, by and among the Company and the investors signatory thereto. |
|---|
| 2024-08-08 | 10-Q | 10.8 | Employment Agreement, dated June 17, 2024, by and between Oncocyte Corporation and Andrea James |
|---|
| 2024-08-08 | 10-Q | 10.7 | Employment Agreement, dated May 20, 2024, by and between Oncocyte Corporation and Ekkehard Schütz |
|---|
| 2024-05-15 | 10-Q | 10.6 | Collaboration Agreement, dated April 5, 2024, between the Company and Bio-Rad Laboratories, Inc. |
|---|
| 2024-04-16 | 10-K | 10.30 | Lease Agreement for Suite 510, dated January 1, 2024, between Insight Genetics, Inc. and MPC Holdings, LLC |
|---|
| 2024-04-16 | 10-K | 10.29 | Lease Agreement for Suite 410, dated January 1, 2024, between Insight Genetics, Inc. and MPC Holdings, LLC |
|---|
| 2024-04-16 | 10-K | 10.28 | Lease Agreement for Suite 103, dated January 1, 2024, between Insight Genetics, Inc. and MPC Holdings, LLC |
|---|
| 2024-04-12 | 8-K | 10.2 | Registration Rights Agreement, dated April 11, 2024, by and among the Company and the investors signatory thereto. |
|---|
| 2024-04-12 | 8-K | 10.1 | Securities Purchase Agreement, dated April 11, 2024, by and among the Company and the investors signatory thereto. |
|---|
| 2023-11-09 | 10-Q | 10.3 | Sublease Agreement, dated August 8, 2023, by and between Oncocyte Corporation and Induce Biologics USA, Inc. |
|---|
| 2023-07-14 | 8-K | 10.1 | Amendment to Amended and Restated Employment Agreement, by and between the Company and Joshua Riggs, dated July 13, 2023. |
|---|
| 2023-06-09 | 8-K | 10.1 | Amended and Restated Employment Agreement, by and between the Company and Joshua Riggs, dated June 6, 2023. |
|---|
| 2023-04-06 | 8-K | 10.1 | Form of Securities Purchase Agreement. |
|---|
| 2023-02-13 | 8-K | 10.1 | Termination Agreement, dated February 7, 2023, by and between Oncocyte Corporation and Life Technologies Corporation |
|---|
| 2023-02-03 | 8-K | 10.1 | First Amendment to Stock Purchase Agreement, dated December 15, 2022, by and among Dragon Scientific, LLC, Oncocyte Corporation and Razor Genomics Inc. |
|---|
| 2022-12-21 | 8-K | 10.3 | Consulting Agreement, by and between the Company and Douglas Ross, dated as of December 16, 2022. |
|---|
| 2022-12-21 | 8-K | 10.2 | Separation Agreement and General Release of All Claims, by and between the Company and Douglas Ross, dated December 16, 2022. |
|---|
| 2022-12-21 | 8-K | 10.1 | Separation Agreement and General Release of All Claims, by and between the Company and Gisela Paulsen, dated December 16, 2022. |
|---|
| 2022-12-05 | 8-K | 10.4 | Amended & Restated Change in Control and Executive Severance Plan Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022. |
|---|
| 2022-12-05 | 8-K | 10.3 | Employment Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 |
|---|
| 2022-12-05 | 8-K | 10.2 | Consulting Agreement, by and between the Company and Ronald Andrews, dated as of December 1, 2022 |
|---|
| 2022-12-05 | 8-K | 10.1 | Separation Agreement and General Release of All Claims, by and between the Company and Ronald Andrews, dated December 1, 2022 |
|---|
| 2022-04-13 | 8-K | 10.1 | Form of Securities Purchase Agreement, among us and certain investors, dated April 13, 2022 |
|---|
| 2022-03-11 | 10-K | 10.43 | Collaboration Agreement, dated January 13, 2022, by and between Oncocyte Corporation and Life Technologies Corporation*† |
|---|
| 2021-12-08 | 8-K | 10.1 | Addendum No. 2 to Exclusive Sublicense Agreement in the PRC Territory, dated December 5, 2021, by and among Razor Genomics, Inc., Oncocyte Corporation, Encore Clinical, Inc., and Burning Rock Biotech Limited |
|---|
| 2021-10-07 | 8-K | 10.1 | Change in Control and Executive Severance Plan Agreement, dated October 4 2021, between Oncocyte Corporation and Gisela Paulsen |
|---|
| 2021-06-28 | 8-K | 10.1 | Amendment of 2018 Equity Incentive Plan |
|---|
| 2021-03-19 | 10-K | 10.44 | Amended and Restated Exclusive License Agreement, effective February 15, 2018, between Razor Genomics, Inc. and the licensor named therein†* |
|---|
| 2021-01-21 | 8-K | 10.1 | Subscription Agreements, dated January 20, 2021, between OncoCyte Corporation and the investors named therein |
|---|
| 2020-12-16 | 8-K | 10.1 | EXCLUSIVE SUBLICENSE AGREEMENT IN THE PRC TERRITORY |
|---|
| 2020-09-28 | 8-K | 10.3 | Reduction in Salary Agreement between OncoCyte Corporation and Tony Kalajian |
|---|
| 2020-09-28 | 8-K | 10.2 | Reduction in Salary Agreement between OncoCyte Corporation and Lyndal Hesterberg |
|---|
| 2020-09-28 | 8-K | 10.1 | Reduction in Salary Agreement between OncoCyte Corporation and Albert Parker. |
|---|
| 2020-07-29 | 10-Q | 10.1 | Employment Agreement, dated March 23, 2020, between OncoCyte Corporation and Douglas Ross* |
|---|
| 2020-05-12 | 8-K | 10.3 | Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Lyndal Hesterberg |
|---|
| 2020-05-12 | 8-K | 10.2 | Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Mitchell Levine |
|---|
| 2020-05-12 | 8-K | 10.1 | Acknowledgement and Agreement, dated May 7, 2020, between OncoCyte Corporation and Ronald Andrews |
|---|
| 2020-05-12 | 10-Q | 10.3 | Loan Deferral Agreement, dated April 2, 2020, between OncoCyte Corporation and Silicon Valley Bank* |
|---|
| 2020-04-29 | 8-K | 10.1 | U.S. Small Business Administration Paycheck Protection Program Note |
|---|
| 2020-04-28 | 8-K | 10.1 | Form of Subscription Agreements, dated April 24, 2020, between OncoCyte Corporation and the investors named therein* |
|---|
| 2020-03-26 | 10-K | 10.36 | Form of Change in Control and Severance Agreement* |
|---|
| 2020-03-26 | 10-K | 10.35 | Oncocyte Corporation Change in Control and Severance Plan* |
|---|
| 2020-03-26 | 10-K | 10.34 | Lease Agreement, dated November 10, 2011, between Insight Genetics, Inc. and MPC Holdings, LLC, as renewed by notice dated January 3, 2019* |
|---|
| 2020-03-26 | 10-K | 10.24 | Employment Agreement, dated May 22, 2019, between OncoCyte Corporation and Padma Sundar* |
|---|
| 2020-03-26 | 10-K | 10.10 | Employment Agreement, dated October 23, 2019, between OncoCyte Corporation and Lyndal Hesterberg |
|---|
| 2020-03-20 | 8-K | 10.1 | Equity Distribution Agreement, dated March 20, 2020 |
|---|
| 2020-01-06 | 8-K | 10.1 | Subscription Agreement, dated January 2, 2020, between Oncocyte Corporation and the investors named therein* |
|---|
| 2019-12-27 | 8-K | 10.1 | Office Lease Agreement, dated December 23, 2019, between OncoCyte Corporation and Cushing Ventures, LLC* |
|---|
| 2019-11-14 | 8-K | 10.1 | Form of Subscription Agreement between OncoCyte Corporation and the investors party thereto |
|---|
| 2019-10-21 | 8-K | 10.2 | Warrant to Purchase Common Stock, dated October 17, 2019, between OncoCyte Corporation and Silicon Valley Bank* |
|---|
| 2019-10-21 | 8-K | 10.1 | First Amendment to Loan and Security Agreement, dated October 17, 2019, between OncoCyte Corporation and Silicon Valley Bank†* |
|---|
| 2019-10-03 | 8-K | 10.4 | Laboratory Services Agreement, dated August 15, 2015, as amended, among OncoCyte Corporation, Encore Clinical, Inc., and Razor Genomics Inc.†* |
|---|
| 2019-10-03 | 8-K | 10.3 | Sublicense and Distribution Agreement, dated September 30, 2019, among OncoCyte Corporation, Encore Clinical, Inc., and Razor Genomics Inc.†* |
|---|
| 2019-10-03 | 8-K | 10.2 | Development Agreement, dated September 30, 2019, among OncoCyte Corporation, Encore Clinical, Inc., and Razor Genomics Inc.†* |
|---|
| 2019-10-03 | 8-K | 10.1 | Form of Minority Holder Stock Purchase Agreement, between OncoCyte Corporation and the persons named therein. |
|---|
| 2019-07-08 | 8-K | 10.1 | Transition Agreement, dated July 1, 2019, between OncoCyte Corporation and William Annett |
|---|
| 2019-06-06 | 8-K | 10.1 | Employment Agreement, dated June 4, 2019, between OncoCyte Corporation and Ronald Andrews |
|---|
| 2019-04-01 | 10-K | 10.26 | Separation Agreement, dated January 22, 2019, between OncoCyte Corporation and Kristine Mechem* |
|---|
| 2018-11-13 | 10-Q | 10.1 | Employment Agreement, dated August 6, 2018, between OncoCyte Corporation and Albert P. Parker* |
|---|
| 2018-08-01 | 8-K | 10.2 | Engagement Agreement, dated July 26, 2018, by and between OncoCyte Corporation and Chardan Capital Markets, LLC |
|---|
| 2018-08-01 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated July 26, 2018, by and among OncoCyte Corporation and the investors signatory thereto |
|---|
| 2018-04-02 | 10-K | 10.24 | Employment Agreement, dated November 15, 2017, between OncoCyte Corporation and Mitchell Levine* |
|---|
| 2018-04-02 | 10-K | 10.XI | Employment Agreement, dated August 31, 2017, between OncoCyte Corporation and Michael Vicari* |
|---|
| 2018-03-29 | 8-K | 10.1 | Form of Securities Purchase Agreement |
|---|
| 2017-07-26 | 8-K | 10.3 | Form of Warrant Exercise Agreement (New Warrant for 50% of shares received on exercise of Original Warrant, at $3.25 exercise price with two-year term, and New Warrant for 50% of shares received on exercise of Original Warrant, at $5.50 exercise price with two-year term) |
|---|
| 2017-07-26 | 8-K | 10.2 | Form of Warrant Exercise Agreement (New Warrant for 50% of shares received on exercise of Original Warrant, at $3.25 exercise price with five-year term) |
|---|
| 2017-07-26 | 8-K | 10.1 | Form of Warrant Exercise Agreement (New Warrant for 100% of shares received on exercise of Original Warrant, at $5.50 exercise price with five-year term) |
|---|
| 2017-04-28 | 10-Q | 10.4 | Employment Termination and Release Agreement, dated February 27, 2017, between OncoCyte Corporation and Karen Chapman* |
|---|
| 2017-02-27 | 10-K | 10.29 | Loan and Security Agreement, dated February 21, 2017, between OncoCyte Corporation and Silicon Valley Bank* |
|---|
| 2017-02-27 | 10-K | 10.26 | Employment Agreement, dated November 1, 2016, between OncoCyte Corporation and Lyndal Hesterberg* |
|---|
| 2017-02-24 | 8-K | 10.2 | Alternate form of Warrant Exercise Agreement |
|---|
| 2017-02-24 | 8-K | 10.1 | Form of Warrant Exercise Agreement |
|---|
| 2016-08-29 | 8-K | 10.2 | Alternate form of Securities Purchase Agreement |
|---|
| 2016-08-29 | 8-K | 10.1 | Form of Securities Purchase Agreement |
|---|
| 2016-08-11 | 10-Q | 10.1 | Second Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology * |
|---|
| 2016-05-24 | 10-K/A | 10.21 | License Agreement, dated January 22, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment)* |
|---|
| 2016-03-30 | 10-K | 10.22 | First Amendment to License Agreement, dated January 25, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology* |
|---|
| 2016-03-30 | 10-K | 10.21 | License Agreement, dated January 22, 2016, between OncoCyte Corporation and The Wistar Institute of Anatomy and Biology (Portions of this exhibit have been omitted pursuant to a request for confidential treatment)* |
|---|